Meropenem and Injection site extravasation - a phase IV clinical study of FDA data

Summary:

Injection site extravasation is reported as a side effect among people who take Meropenem (meropenem), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Ondansetron, and have Nausea.

The phase IV clinical study analyzes which people have Injection site extravasation when taking Meropenem. It is created by eHealthMe based on reports of 33,250 people who have side effects when taking Meropenem from the FDA, and is updated regularly.

What is Meropenem?

Meropenem has active ingredients of meropenem. eHealthMe is studying from 33,295 Meropenem users. Check the latest studies of Meropenem.

What is Injection site extravasation?

Injection site extravasation (flow of (blood or lymph) from injection site) is found to be associated with 555 drugs and 730 conditions by eHealthMe. Check the latest studies of Injection site extravasation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

33,250 people reported to have side effects when taking Meropenem.
Among them, 17 people (0.05%) have Injection site extravasation.

Could Meropenem cause Injection site extravasation?

Among these 17 people:

How long have people been on Meropenem when they have Injection site extravasation? *

What is the gender of people who have Injection site extravasation when taking Meropenem? *

female: 5.88 %
male: 94.12 %

What is the age of people who have Injection site extravasation when taking Meropenem? *

What are other drugs people take besides Meropenem? *

Ondansetron: 12 people, 70.59%
Ondansetron Hydrochloride: 1 person, 5.88%

What are other side effects people have besides Injection site extravasation? *

Catheter Site Pain: 13 people, 76.47%
Peripheral Swelling: 11 people, 64.71%
Injection Site Swelling: 11 people, 64.71%
Injection Site Pain: 11 people, 64.71%
Extravasation (leakage of a fluid): 9 people, 52.94%
Catheter Site Swelling: 2 people, 11.76%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 1 person, 5.88%
Infusion Site Haematoma (localized swelling filled with blood at infusion site): 1 person, 5.88%

What are the existing conditions these people have? *

Nausea (feeling of having an urge to vomit): 13 people, 76.47%
Sepsis (a severe blood infection that can lead to organ failure and death): 12 people, 70.59%
Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon): 1 person, 5.88%
Cytomegalovirus Enterocolitis (virus infection of intestine and colon): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Meropenem and have Injection site extravasation?

- Check whether Injection site extravasation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Meropenem:

Meropenem (33,295 reports)

Browse all side effects of Meropenem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site extravasation:

Injection site extravasation (555 drugs)

Browse all the conditions that are associated with Injection site extravasation:

Injection site extravasation (730 conditions)

Related publications that referenced our studies

Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on meropenem (the active ingredients of Meropenem) and Meropenem (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.